[1] 杨之洵, 郑荣寿, 张思维, 等. 中国胃癌发病趋势及预测[J]. 中国肿瘤, 2019, 28(5):321-326. [2] Deo SVS, Sharma J, Kumar S.GLOBOCAN 2020 report on global cancer burden: Challenges and opportunities for surgical oncologists[J]. Ann Surg Oncol, 2022, 29(11):6497-6500. [3] Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. [4] Cao W, Chen HD, Yu YW, et al.Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7):783-791. [5] 中国中西医结合学会检验医学专业委员会. 中国早期胃癌筛查检验技术专家共识[J]. 中华检验医学杂志,2023,46(4):347-359. [6] Tonkic A, Vukovic J, Vrebalov Cindro P, et al.Diagnosis of Helicobacter pylori infection: A short review[J]. Wien Klin Wochenschr, 2018, 130(17-18):530-534. [7] Zhou MJ, Huang RJ.Catching up with the world: Pepsinogen screening for gastric cancer in the United States[J]. Cancer Epidemiol Biomarkers Prev, 2022, 31(7):1257-1258. [8] Zhou JP, Liu CH, Liu BW, et al.Association of serum pepsinogens and gastrin-17 with Helicobacter pylori infection assessed by urea breath test[J]. Front Cell Infect Microbiol, 2022, 12:980399. [9] 国家消化系疾病临床医学研究中心, 中华医学会消化内镜学分会, 中华医学会健康管理学分会, 等. 中国早期胃癌筛查流程专家共识意见(草案,2017年,上海)[J]. 中华消化杂志,2018,38(2):87-92. [10] 中华人民共和国国家卫生健康委员会医政医管局. 胃癌诊疗指南(2022年版)[J]. 中华消化外科杂志, 2022, 21(9):1137-1164. [11] 李俊, 姚保栋, 李为希, 等. 血清幽门螺杆菌抗体、胃蛋白酶原、胃泌素-17检测对5 552名社区胃癌高危人群的筛查研究[J]. 中国肿瘤, 2019, 28(8):629-635. [12] Lee SP, Lee SY, Kim JH, et al.Link between serum pepsinogen concentrations and upper gastrointestinal endoscopic findings[J]. J Korean Med Sci, 2017, 32(5):796-802. [13] 乔正梅,张雷,葛君琍. 幽门螺杆菌IgG抗体、胃蛋白酶原及胃泌素-17检测与胃癌的相关性分析[J]. 中国卫生检验杂志,2022,32(14):1742-1745. [14] Kim YJ, Chung WC.Is serum pepsinogen testing necessary in populationbased screening for gastric cancer?[J]. Korean J Intern Med, 2020, 35(3):544-546. [15] Yuan L, Zhao JB, Zhou YL, et al.Type I and type II Helicobacter pylori infection status and their impact on gastrin and pepsinogen level in a gastric cancer prevalent area[J]. World J Gastroenterol, 2020, 26(25):3673-3685. [16] Wu C, Liu Y, Shi F, et al.The relationship of serum gastrin-17 and oral mucositis in head and neck carcinoma patients receiving radiotherapy[J]. Discov Oncol, 2022, 13(1):110. [17] 韩文鹏,刘静,王浩文.幽门螺杆菌感染患者胃黏膜病变表现与胃蛋白酶原和胃泌素-17水平的相关性[J].热带医学杂志,2023,23(4):488-492. [18] 张培莉, 刘义庆, 张炳昌, 等. 体检人群血清胃蛋白酶原、胃泌素-17与幽门螺杆菌抗体分型检测临床分析[J]. 现代检验医学杂志, 2017, 32(4):32-35. [19] 陈敏,孙海兵,费梦雪.胃黄斑瘤与胃泌素17、胃蛋白酶原及幽门螺杆菌的关系[J].分子诊断与治疗杂志,2023,15(2):253-256. [20] 成晓芬, 闵淑慧, 郭芮绮, 等. 1990—2019年中国胃癌发病与死亡率年龄-时期-队列分析及2020—2030年变化趋势预测[J]. 中国肿瘤, 2023, 32(6):454-461. [21] 靳晓云,王洋,符立金.北京市平谷区体检人群幽门螺杆菌感染状况及相关因素研究[J].华南预防医学,2022,48(11):1314-1318. [22] 赵应飞, 田雪梅, 赵佳, 等. C 13呼气试验、血清胃蛋白酶原及胃癌相关标志物联合检测对健康体检的价值[J]. 国际检验医学杂志, 2016, 37(5):608-610. [23] Nagy P, Johansson S, Molloy‐Bland M. Systematic review of time trends in the prevalence of Helicobacter pylori infection in China and the USA[J]. Gut Pathog, 2016, 8:8. [24] 韩玉刚, 崔云朋, 李静, 等. 济南地区自然人群幽门螺杆菌感染情况及其免疫分型研究[J]. 检验医学与临床, 2020,17(5):630-632. [25] Zagari RM, Rabitti S, Greenwood DC, et al.Systematic review with meta‐analysis: Diagnostic performance of the combination of pepsinogen, gastrin-17 and anti‐Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis[J]. Aliment Pharmacol Ther, 2017, 46(7):657-667. [26] Wu JY, Lee YC, Graham DY.The eradication of Helicobacter pylori to prevent gastric cancer:A critical appraisal[J]. Expert Rev Gastroenterol Hepato, 2019, 13(1):17-24. |